HighMark Wealth Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

HighMark Wealth Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$630	Hold	130	–	–	﹤0.01%	513
2026 Q1	$304	Hold	130	–	–	﹤0.01%	521
2025 Q4	$175	Hold	130	–	–	﹤0.01%	568
2025 Q3	$196	Hold	130	–	–	﹤0.01%	582
2025 Q2	$151	Hold	130	–	–	﹤0.01%	597
2025 Q1	$207	Hold	130	–	–	﹤0.01%	550
2024 Q4	$394	Hold	130	–	–	﹤0.01%	541
2024 Q3	$478	Hold	130	–	–	﹤0.01%	545
2024 Q2	$532	Hold	130	–	–	﹤0.01%	533
2024 Q1	$2.05K	Hold	130	–	–	﹤0.01%	469
2023 Q4	$1.97K	Hold	130	–	–	﹤0.01%	471
2023 Q3	$2.61K	Hold	130	–	–	﹤0.01%	429
2023 Q2	$3.67K	Buy	+130	New	+$3.12K	﹤0.01%	395

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HighMark Wealth Management's ZNTL Position: Q2 2026 in Review

HighMark Wealth Management held its Zentalis Pharmaceuticals (ZNTL) position steady in Q2 2026 at 130 shares worth $630. The position accounts for ﹤0.01% of the portfolio, ranked #513.

HighMark Wealth Management first reported a position in ZNTL in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.67K in Q2 2023. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

HighMark Wealth Management held 130 shares of Zentalis Pharmaceuticals worth $630 as of Q2 2026.
HighMark Wealth Management left its Zentalis Pharmaceuticals share count unchanged in Q2 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #513 holding.
HighMark Wealth Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
HighMark Wealth Management's Zentalis Pharmaceuticals position peaked at $3.67K in Q2 2023.
114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.